Journal
EXPERT REVIEW OF VACCINES
Volume 14, Issue 8, Pages 1047-1049Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.1051470
Keywords
9-valent vaccine; cervical disease; Gardasil; human papilloma virus; vaccination
Categories
Funding
- Cancer Research UK [16891] Funding Source: researchfish
Ask authors/readers for more resources
A trial of 14,215 women aged between 16 and 26 years comparing a new vaccine with nine human papilloma virus types - four from the licensed Gardasil vaccine (types 6, 11,16 and 18) and five new ones (types 31, 33, 45, 52 and 58) to Gardasil - has shown improved protection against cervical cancer precursor lesions. Antibody response for the four original Gardasil types was not inferior and a 96.3% reduction in high-grade cervical disease for the other five types not in Gardasil was seen in the per-protocol population. Six-month persistent infection was reduced by 96% for these types. There were no serious safety concerns, although injection site reactions were more common with the new vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available